Return to the catalog
CJC-1295 with DAC
PopularIn Stock2mg vial

CJC-1295 with DAC

Long-acting peptide studied for sustained growth-hormone signalling in research models.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 600.00
5+ vials — save 33%R 400.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

CJC-1295 with DAC is a modified version of a natural hormone signal called GHRH, which tells the body to release growth hormone. The DAC attachment helps it remain active in the bloodstream for longer than shorter-acting versions. Researchers study its effects on growth-hormone patterns, recovery, and body-composition markers.

Why researchers reach for CJC-1295 with DAC

Extended half-life

Albumin binding via DAC gives a multi-day plasma profile in research.

Pulsatile GH studies

Used to probe growth-hormone-releasing pathways in vivo.

Pairs with GHRPs

Common comparator alongside Ipamorelin in preclinical protocols.

Key features

  • ≥99% HPLC purity
  • DAC-conjugated tetrasubstituted GHRH(1-29)
  • Mass-spec verified
  • Cold-chain dispatch

How it works

GHRH receptor agonism

Binds pituitary GHRH receptors to trigger GH release.

Albumin tethering

Maleimide DAC forms covalent bond with plasma albumin cysteine-34.

Sustained IGF-1 tone

Extends downstream IGF-1 elevation in preclinical models.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 1 mg/mL (1000 mcg/mL)
Reported research range1–2 mg/weekReference only

Tracking this compound? Registered researchers can log active CJC-1295 with DAC protocols in their private Research Log.

Timing in research protocols

Weekly or every-other-week dosing — clock time is not a variable.

  • The pivotal human pharmacokinetic study (Teichman et al., JCEM 2006) used weekly or biweekly subcutaneous doses across 28–49 day study periods.
  • Reported elimination half-life of roughly 5.8–8.1 days, with IGF-I still elevated up to 28 days after repeated doses.
  • Because of that long half-life, time of day and fed or fasted state are pharmacologically immaterial; the spacing between doses is the operative variable.
  • Study durations in the published literature run to approximately seven weeks.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 (modified GRF 1-29 with DAC)
Class
GHRH analogue + DAC
Molecular weight
3367.9 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
2 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on CJC-1295 with DAC. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#GHRH#growth-hormone#long-acting

Cart (0)

Your cart is empty